Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Improved seroprevalence and antibody response after third COVID-19 vaccination

by Medical Finance
in Coronavirus
Study: Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study. Image Credit: BaLL LunLa/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to Research Square* preprint server, researchers evaluated the immunogenicity of a third coronavirus disease 2019 (COVID-19) vaccination in antibody deficient subjects.

Study: Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study. Image Credit: BaLL LunLa/Shutterstock
Study: Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study. Image Credit: BaLL LunLa/Shutterstock

Background

Studies have reported that the antibody responses following two-dose vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) significantly diminish in those with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID). The seroprevalence of antibodies against SARS-CoV-2 has been 54.8% post-double immunization, as estimated by the COV-AD (COVID-19 in Patients with Antibody Deficiency) study.

The reduced neutralizing potency of sera from doubly-vaccinated subjects against SARS-CoV-2 Delta and Omicron variants has been concerning. In light of this, the third vaccination with a messenger ribonucleic acid (mRNA)-based vaccine was recommended in the United Kingdom (UK) to augment the immune responses.

Few studies on immunosuppressed subjects have reported immunogenicity after the third vaccine dose. However, the immunogenicity in PID and SID subjects post-third vaccination has not been characterized. These individuals show inherent problems in mounting an immune response following infection or vaccination.

About the study

In the present study, researchers examined the immunological responses to a third COVID-19 vaccine dose in antibody deficient subjects relative to control subjects. Participants were recruited as part of the COV-AD study if they were aged 18 years or above and were recipients of immunoglobulin (Ig) replacement therapy, or antibiotic prophylaxis. A cohort of healthy participants was included as a control group.

The study participants received two BNT162b2 or ChAdOx1 vaccines in an extended schedule followed by a third BNT162b2 vaccine or mRNA-1273 vaccine. Where possible, venous blood or dried blood spot (DBS) sampling was carried out one-to-two months post-second vaccination (V2), up to four months before the third dose (V3), or one-to-two months post-third dose (V3). Otherwise, a single sample was collected randomly after the second vaccination without any fixed time point.

The samples were assessed for total antibodies against the SARS-CoV-2 spike (S) protein, which was reported as IgG, A, M (IgGAM) ratio, and results ≥ 1 were considered seropositive. 

Seropositivity was defined as the proportion of seropositive subjects, and serological results were reported as median IgGAM ratios. IgG responses against SARS-CoV-2 Wuhan or Omicron S proteins were estimated with an in-house enzyme-linked immunosorbent assay (ELISA). Vero cells were used for live virus neutralization tests (VNTs). T lymphocyte responses were evaluated using a T-SPOT COVID assay based on the ELISPOT assay.

Results

The researchers observed a significant waning of anti-S antibodies in the six months post-V2. However, seropositivity was markedly elevated post-V3 in the COV-AD subjects. The IgGAM ratios were 1.88 and 4.54 pre-V3 and post-V3, respectively. This indicates that the magnitude of antibody responses in COV-AD subjects significantly increased post-V3.

Nonetheless, the responses were significantly lower in COV-AD subjects relative to control subjects. No significant differences in seroprevalence or magnitude of antibody responses were found between BNT162b2 and ChAdOx1 vaccinees post-six months of V2. Similarly, seroprevalence was insignificant post-V3 across the two cohorts of vaccinees.

Nonetheless, vaccine-induced responses were heterogeneous between PID and SID subjects. Notably, antibodies were not mounted in response to vaccines in those with X-linked agammaglobulinemia (XLA). Individuals with common variable immunodeficiency disorder (CVID) exhibited the lowest post-V3 seroprevalence and median IgGAM ratios.

Contrastingly, those with specific polysaccharide antibody deficiency (SPAD), the non-responders to pneumococcal vaccination, showed immune responses to COVID-19 vaccination.

Paired samples collected one to two months post-V2 and V3 were available for 64 individuals. Seroprevalence increased from 59.4% post-V2 to 75% post-V3 in the subjects, highlighting the immunogenicity of the third vaccine in non-responders. Additionally, paired specimens were available for 37 subjects at pre-and post-V3 timepoints.

IgG responses against Wuhan S and Omicron S proteins were evaluated in the subjects. At the pre-V3 point, IgG seroprevalence was 62.2% against Wuhan S protein and 40.5% against Omicron S protein, increasing to 78.4% and 67.5%, respectively, post-V3. Nevertheless, IgG seroprevalence was lower in COV-AD subjects relative to controls. Serum VNT performed against the Wuhan strain of SARS-CoV-2 revealed high neutralizing capacity after V3. T cell responses were detected in 47.5% of subjects post-V2, 46.4% pre-V3, and 59.6% post-V3 and were more prominent and quantitatively greater in individuals with COVID-19 history.

Conclusions

The study results showed that a third COVID-19 vaccination was associated with a significant increase in seroprevalence of anti-S protein antibodies among COV-AD subjects. Moreover, broadly cross-reactive immune responses were observed against Omicron. However, immunological responses were lower compared to controls.

Notably, 32.5% of the study participants failed to induce binding antibodies to Omicron. In COVID-19-naïve subjects, heterologous vaccination was associated with a high frequency of detectable T cells. However, whether further vaccinations would benefit those who could not mount a serological response following three vaccine doses remains to be investigated.

The authors of the present study recommended prioritization of non-responders to vaccines for antiviral or monoclonal antibody therapies if found SARS-CoV-2 positive.

*Important notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Extracellular Vimentin Is an Attachment Factor That Facilitates SARS-Cov-2 Entry into Human Endothelial Cells. Image Credit: Kateryna Kon / Shutterstock.com

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

by Medical Finance
May 20, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the coronavirus disease 2019 (COVID-19) pandemic, which has claimed over 5.8...

Study: Excess COVID-19 associated deaths among the unvaccinated population ≥18 years old in the US, May 30 – December 4, 2021. Image Credit: Lightspring/Shutterstock

Retrospective study estimates the substantial number of COVID-19 deaths among the unvaccinated

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers from the United States (US) performed a retrospective analysis...

Study: SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. Image Credit: Dotted Yeti / Shutterstock.com

SpaceX employee study estimates odds ratio for SARS-CoV-2 reinfection

by Medical Finance
May 20, 2022
0

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the population that had little pre-existing immunity...

Study: Epigenetic Memory of COVID-19 in Innate Immune Cells and Their Progenitors. Image Credit: Elizaveta Galitckaia/Shutterstock

Study suggests that epigenetic memory in innate immune cells could be the key to explaining long COVID

by Medical Finance
May 20, 2022
0

A fascinating, new study may provide a partial explanation for the long-term immunologic phenomena associated with coronavirus disease 2019 (COVID-19),...

Study: The Utility of Telemedicine In Managing Patients After COVID-19. Image Credit: Cryptographer / Shutterstock.com

How has telemedicine assisted COVID-19 patients?

by Medical Finance
May 20, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic has been caused by the spread of a contagious virus known as the...

N95 Respirator

Can N95 respirators be safely re-processed?

by Medical Finance
May 20, 2022
0

Can N95 respirators be safely re-processed? We speak to Christina Yen, an infectious diseases physician, to find out. Please can...

Next Post
Study: Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. Image Credit: NIAID

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Hormone 620x480
    Blocking an enzyme activity inside fat cells can reduce obesity in mice
  • Study: Β-Amyloid Deposits in Young COVID Patients. Image Credit: Kateryna Kon / Shutterstock.com
    Beta-amyloid deposits found in young patients with COVID-19
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply